We are live on ! Find out more
BSX icon

Boston Scientific

1,222 hedge funds and large institutions have $90.8B invested in Boston Scientific in 2024 Q1 according to their latest regulatory filings, with 155 funds opening new positions, 443 increasing their positions, 451 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 155 | Existing positions closed: 69

16% more capital invested

Capital invested by funds: $78.3B → $90.8B (+$12.4B)

6% more funds holding

Funds holding: 1,1481,222 (+74)

0% more funds holding in top 10

Funds holding in top 10: 2727 (0)

2% less repeat investments, than reductions

Existing positions increased: 443 | Existing positions reduced: 451

3% less call options, than puts

Call options by funds: $468M | Put options by funds: $482M

2.1% less ownership

Funds ownership: 92.48%90.38% (-2.1%)

Holders
1,222
Holders Change
+74
Holders Change %
+6.45%
% of All Funds
17.6%
Holding in Top 10
27
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.39%
New
155
Increased
443
Reduced
451
Closed
69
Calls
$468M
Puts
$482M
Net Calls
-$13.7M
Net Calls Change
+$11.3M
Name Holding Trade Value Shares
Change
Change in
Stake
RWM
401
RBA Wealth Management
California
$4.76M -$78.4K -1,220 -2%
MYLI
402
Meiji Yasuda Life Insurance
Japan
$4.7M +$1.46M +22,725 +50%
ZCM
403
Ziegler Capital Management
Illinois
$4.65M +$4.37M +67,923 New
LS
404
Livforsakringsbolaget Skandia
Sweden
$4.64M
SPC
405
Spirepoint Private Client
Florida
$4.61M +$4.33M +67,281 New
CIS
406
Capital International Sarl
California
$4.58M +$4.3M +66,823 New
SP
407
Saranac Partners
$4.58M -$508K -7,897 -11%
Wealth Enhancement Advisory Services
408
Wealth Enhancement Advisory Services
Minnesota
$4.52M +$417K +6,485 +11%
CAG
409
Crestwood Advisors Group
Massachusetts
$4.49M +$203K +3,164 +5%
CI
410
Cavalier Investments
Georgia
$4.48M +$235K +3,651 +6%
TFA
411
Transamerica Financial Advisors
Florida
$4.37M +$3.73M +58,041 +1,017%
CI
412
Capital International
California
$4.36M +$4.1M +63,706 New
RBA
413
Richard Bernstein Advisors
New York
$4.36M
AIM
414
Achmea Investment Management
Netherlands
$4.36M
DAS
415
Dynamic Advisor Solutions
Arizona
$4.33M +$38.5K +599 +1%
CB
416
Commerce Bank
Missouri
$4.28M -$14.2K -221 -0.4%
SAM
417
Simplify Asset Management
Nevada
$4.28M +$2.15M +33,370 +115%
LP
418
LMR Partners
United Kingdom
$4.26M +$1.07M +16,592 +36%
NA
419
NewEdge Advisors
Louisiana
$4.15M +$1.26M +19,573 +48%
A
420
AustralianSuper
Australia
$4.15M -$805K -12,521 -17%
SPIA
421
Steward Partners Investment Advisory
New York
$4.05M +$2.17M +33,721 +133%
MLICM
422
Metropolitan Life Insurance Company (MetLife)
New York
$4.05M -$33K -514 -0.9%
TCM
423
Tandem Capital Management
New Jersey
$4M -$8.04K -125 -0.2%
Mercer Global Advisors
424
Mercer Global Advisors
Colorado
$3.98M +$597K +9,280 +19%
NIM
425
NEOS Investment Management
Connecticut
$3.92M +$1.89M +29,430 +106%

BSX Hedge Fund Activity: Q1 2024 in Review

1,222 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q1 2024, worth a combined $90.8B — up 16% from $78.3B a quarter earlier.

Buyers outnumbered sellers: 155 funds opened new BSX positions and 69 closed out — a net gain of 86 holders — while 443 added to existing stakes and 451 trimmed.

The largest buyer was Franklin Resources, adding an estimated $910M. The largest seller was Morgan Stanley, cutting an estimated $1.26B.

  • 1,222 institutional investors held Boston Scientific (BSX) as of Q1 2024, up from 1,148 in Q4 2023.
  • Funds reported $90.8B of Boston Scientific stock for Q1 2024, up 16% quarter-over-quarter.
  • 155 funds opened new Boston Scientific positions in Q1 2024 and 69 closed out, a net change of +86 holders.
  • The largest Boston Scientific buyer in Q1 2024 was Franklin Resources, an estimated $910M added.
  • The largest Boston Scientific seller in Q1 2024 was Morgan Stanley, an estimated $1.26B sold.

Based on aggregated 13F filings for Q1 2024.